AbbVie (ABBV) Wins A New Lymphoma Nod, Is The Stock Still Cheap?

AbbVie (ABBV) just picked up a fresh regulatory win in oncology, with Health Canada granting a new follicular lymphoma indication for EPKINLY in combination therapy. That gives investors another data point on AbbVie’s expanding cancer portfolio.

Across those headlines, AbbVie’s share price has moved steadily higher, with a year to date share price return of 15.3% and a one year total shareholder return of 23.5%. The three and five year total shareholder returns, at roughly 97% and 191% respectively, point to momentum that has been building over several years rather than just on the latest oncology win.

Capitalize on AbbVie’s oncology momentum by scanning a curated 31 high quality undervalued stocks that pair strong cash flows with solid balance sheets.

AbbVie’s strong multi year run now meets fresh oncology headlines and a richer share price. Are you paying for durable cash generation or for a burst of optimism that pushed the stock ahead of its fundamentals?

Most Popular Narrative: 5% Undervalued

AbbVie last closed at $264.34, while the most followed narrative pegs fair value at $278.61 using a 7.73% discount rate. That gap frames the current oncology headlines inside a broader story about cash flows and pipeline depth.

Ongoing post Humira diversification, where management reports that Humira erosion of about US$18b has been offset by roughly US$28b of growth from other platforms and that 2026 guidance is almost US$10b above the pre Humira peak, reinforces the case that newer franchises can keep supporting overall revenue and adjusted EPS.

See why 317 investors see AbbVie as 5% undervalued.

Result: Fair Value of $278.61 (UNDERVALUED)

Still, AbbVie’s story can change quickly if drug pricing reforms have a stronger impact than expected or if key oncology therapies face faster competitive pressure.

Find out about the key risks to this AbbVie narrative.

Another View: AbbVie’s Rich P/E Tells A Different Story

On cash flows, AbbVie screens as attractive, with the stock trading about 40.7% below the SWS future cash flow value of $445.78. The P/E picture is very different. AbbVie trades at 74.5x earnings versus 28.6x for peers and a fair ratio of 43.4x, which points to valuation risk if sentiment cools.

When one model says underpriced and another flags a rich multiple versus both peers and a fair ratio the market could move toward, which signal do you put more weight on for AbbVie over the next few years?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on AbbVie’s valuation story can cut both ways, so move quickly, test the numbers yourself, and weigh the 3 key rewards and 4 important warning signs.

Looking for more ideas beyond AbbVie?

Do not stop with AbbVie. Broaden your watchlist with fresh opportunities that match your risk appetite and income goals before others move first.

Use the Simply Wall Street Screener to uncover more stocks and investment angles that could complement how AbbVie fits into your portfolio.

• Target potential mispricing by scanning a curated set of quality businesses on the 31 high quality undervalued stocks that combine strong fundamentals with appealing valuations.
• Build more consistent income by reviewing a focused group of higher yield opportunities across the 8 dividend fortresses that balance payouts with financial strength.
• Dial down portfolio stress by filtering for sturdier balance sheets through the 29 resilient stocks with low risk scores that aim to keep risk scores on the lower side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com